Perspectives on long-acting dihydropiridine calcium antagonists in treatment and prophylaxis of chronic kidney disease


Cite item

Full Text

Abstract

Long-acting dihydropiridine calcium antagonists in treatment and prevention of chronic kidney disease are discussed

References

  1. Coresh J., Selvin E., Stevens L.A. et al. Prevalence of chronic kidney disease in the United States. J.A.M.A. 2007; 298(17): 2038-2047
  2. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50 - 55
  3. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии. Нефрология. 2005; 9(3): 7 - 12
  4. Кутырина И.М., Мартынов СА., Швецов М.Ю. и др. Артериальная гипертония при хроническом гломерулонефрите: частота выявления и эффективность лечения. Тер. арх. 2004; 9: 10 - 15
  5. Siamopoulos K.C., Kalaitzidis R.G. Inhibition of the renin-angiotensin system and chronic kidney disease. Int. Urol. Nephrol. 2008; 40(4): 1015-1025
  6. Peralta C.A., Hicks L.S., Chertow G.M. et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension. 2005; 45(6): 1119-1124
  7. Plantinga L.C., Miller E.R. 3rd, Stevens L.A. et al.; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension. 2009; 54(1): 47-56
  8. Duru O.K., Li S., Jurkovitz C. et al. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am. J. Kidney Dis. 2008; 51(2): 192-198
  9. Российское Медицинское Общество по Артериальной Гипертонии - Всероссийское Научное Общество Кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008
  10. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Сердце. 2005; 4(3): 120 - 126
  11. Jameson K., Weber M.A., Bakris G.L. et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417 - 2428
  12. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601 - 1608
  13. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997; 349(9069): 1857-1863
  14. Agodoa L.Y., Appel L., Bakris G.L. et al.; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J.A.M.A. 2001; 285(21): 2719-2728
  15. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345: 851 - 860
  16. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118): 1755-1762
  17. Ruilope L.M., Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J. Am. Soc. Nephrol. 2001; 12(2): 218-225
  18. Staessen J.A., Fagard R., Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757 - 764
  19. Voyaki S.M., Staessen J.A., Thijs L. et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J. Hypertens. 2001; 19: 511 - 519
  20. Gerber L.M., Shmukler C., Alderman M.H. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch. Intern. Med. 1992; 152: 373 - 377
  21. Cirillo M., Stellato D., Laurenzi M. et al. Pulse pressure and isolated systolic hypertension: association with microalbuminuria. The GUBBIO Study Collaborative Research Group. Kidney Int. 2000; 58(3): 1211-1218
  22. Gerdts E., Papademetriou V., Palmieri V. et al.; Losartan Intervention For End (LIFE) point reduction in hypertension study. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am. J. Cardiol. 2002; 89(4): 399-402
  23. Klag M.J., Whelton P.K., Randall B.L. et al. End-stage renal disease in African-American and white men: 16-year MRFIT findings. J.A.M.A. 1997; 277: 1293 - 1298
  24. Domrongkitchaiporn S., Sritara P., Kitiyakara C. et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J. Am. Soc. Nephrol. 2005; 16: 791 - 799
  25. Vikse B.E., Aasarød K., Bostad L., Iversen B.M. Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol. Dial. Transplant. 2003; 18(3): 517-523
  26. Fesler P., Ribstein J., du Cailar G., Mimran A. Determinants of cardiorenal damage progression in normotensive and never-treated hypertensive subjects. Kidney Int. 2005; 67(5): 1974-1979
  27. Mimran A. Consequences of elevated pulse pressure on renal function. J. Hypertens. Suppl. 2006; 24(3): S3-S7
  28. Fesler P., Safar M.E., du Cailar G. et al. Pulse pressure is an independent determinant of renal function decline during treatment of essential hypertension. J. Hypertens. 2007; 25(9): 1915-1920
  29. Verhave J.C., Fesler P., du Cailar G. et al. Elevated pulse pressure is associated with low renal function in elderly patients with isolated systolic hypertension. Hypertension. 2005; 45(4): 586-591
  30. Liu L., Zhang Y., Liu G.; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens. 2005; 23(12): 2157-2172
  31. Dougall H.T., McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996; 15(2): 91-106
  32. Schaefer R.M., Aldons P.M., Burgess E.D. et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int. J. Clin. Pract. 1998; 52(6): 381-386
  33. Bicchi M., Vedovini G., Cappelli R. et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology. 1998; 49(5): 373-380
  34. Herlitz H., Harris K., Risler T. et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol. Dial. Transplant. 2001; 16(11): 2158-2165
  35. Cattran D.C., Alexopoulos E., Heering P. et al. Cyclosporin in idiopathic glomerular disease associated with the nephritic syndrome: workshop recommendations. Kidney Int. 2007; 72(12): 1429 - 1447
  36. Sørensen S.S., Skovbon H., Eiskjaer H. et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol. Dial. Transplant. 1992; 7(1): 69-78
  37. Pedersen E.B., Madsen J.K., Sørensen S.S., Zachariae H. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies. Kidney Int. Suppl. 1996; 55: S94-S96
  38. Madsen J.K., Sørensen S.S., Hansen H.E., Pedersen E.B. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol. Dial. Transplant. 1998; 13(9): 2327-2334

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies